TBXA2R and Hermansky-Pudlak syndrome: Although they are mainly used to treat allergic asthma, coronary artery disease, and other diseases [173], we expect that the early clinical transformation of TBXA2R signaling pathway therapy will be able to improve the prognosis of HPS-PF patients.